There is no single GLP-1 dosage for weight loss. Dose schedules are specific to the prescribed product, its approved use, its dosage form, and the patient. A licensed clinician should select and monitor treatment using the current official prescribing information.
Important safety information for FDA-approved branded medicines. Wegovy contains semaglutide and is an FDA-approved prescription medicine from Novo Nordisk A/S. Zepbound contains tirzepatide and is an FDA-approved prescription medicine from Eli Lilly and Company. Ozempic and Mounjaro are FDA-approved prescription medicines for type 2 diabetes, not weight-loss products. These medicines carry a boxed warning about the risk of thyroid C-cell tumors. They are contraindicated for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Serious risks can include pancreatitis, gallbladder problems, acute kidney injury, severe stomach problems, serious allergic reactions, low blood sugar with certain diabetes medicines, and diabetic retinopathy complications. Review the official Prescribing Information and Medication Guides for Wegovy, Zepbound, Ozempic, and Mounjaro.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Why one dosage chart cannot cover the class
“GLP-1” describes a medication class or mechanism, not one prescription. Products can contain different active ingredients, have different approved uses, and come in different dosage forms. Even products containing the same active ingredient can have different labeling and delivery systems.
That means a dose written for one product should never be transferred to another. Numbers from a friend, a forum, or an old prescription do not provide safe instructions. The official product label and the individual prescription control.
How labeled dose escalation works
For approved medicines used in chronic weight management, official labeling generally starts treatment at a lower dose and describes stepwise increases over time. This process is often called dose escalation or titration. The exact schedule, available strengths, maintenance options, and instructions for missed doses are product-specific.
The lower starting step is part of the labeled approach to treatment. It is not a promise that every patient will advance on the same timetable. A prescriber may need to consider tolerability, side effects, interruptions, other medicines, and the current label before giving instructions.
This page intentionally does not reproduce a dosing table. Labels can be updated, and a table separated from its full warnings can be misused as personal directions. Use the manufacturer links above and follow the prescription label supplied by your pharmacy.
What a clinician considers
Before prescribing, a clinician should review the intended use, medical history, current medicines, allergies, contraindications, and relevant risks. During follow-up, the clinician may ask about stomach symptoms, hydration, blood sugar concerns, other medicines, and whether treatment has been interrupted.
Dose decisions are not based only on a target weight or on wanting faster progress. More medicine is not automatically better, and changing a schedule can increase risk. The prescribed plan may differ from another person’s plan for legitimate clinical reasons.
Contact the prescriber if side effects are difficult, if several doses were missed, if you cannot fill the prescribed strength, or if another clinician changes your medicines. Do not double a dose or create a restart schedule yourself.
FDA-approved products for chronic weight management
FDA approval applies to a specific product, labeled population, and use. Wegovy and Zepbound have official labeling for chronic weight management in defined patients, along with other labeled information. A clinician determines whether a patient meets the relevant criteria and whether the benefits and risks support treatment.
The labeled instructions for approved products should be read as a whole. Dosing sections sit alongside contraindications, boxed warnings, adverse reactions, drug interactions, use in specific populations, storage directions, and missed-dose instructions. Pulling out a dose without that context is unsafe.
Ozempic and Mounjaro have different labeled indications. A shared ingredient family or mechanism does not make product names, indications, or dose schedules interchangeable.
Compounded GLP-1 medications
Compounded semaglutide and compounded tirzepatide are pharmacy-prepared medications. They are separate from the FDA-approved finished drug products described above.
Compounded medications are not FDA-approved. FDA does not review them for safety, effectiveness, or manufacturing quality.
Compounded semaglutide and compounded tirzepatide are not Zepbound, Mounjaro, Ozempic, or Wegovy. Each is not a generic version of any approved drug and is not interchangeable with one. An approved product’s dosing chart should not be treated as instructions for a compounded medication.
A compounded medication may be dispensed only pursuant to a valid prescription issued by a licensed clinician after a clinical evaluation, from a state-licensed pharmacy. The individual prescription and dispensing label provide the directions. A clinician decides whether the prescription is appropriate and must address questions about its use. FDA provides general background on human drug compounding.
Never convert units, concentrations, syringe markings, or doses using an online post. A concentration or dosage form may differ, and a conversion mistake can cause serious harm. Confirm every unclear instruction with the prescriber and dispensing pharmacist before using the medication.
Missed doses and treatment interruptions
Missed-dose directions vary by product and by how long treatment has been interrupted. Check the current Medication Guide and call the prescriber or pharmacist. Do not take extra medication to make up for a missed dose unless the official instructions and your clinician specifically direct it.
An interruption may require a new clinical decision, especially if side effects occurred or your health and medicines changed. Storage problems also belong with the pharmacist or manufacturer, not an improvised dosing adjustment.
Body Good’s clinical role and fees
Body Good provides clinical evaluation and ongoing support through the program described at intake. A licensed clinician reviews the individual situation and determines whether any prescription and dose are appropriate. No outcome or prescription is guaranteed.
Body Good’s prices are Body Good service fees for the described program. They are not medication prices and are not a quote for any individual. Eligibility is determined by a clinician. Medication cost is separate and is not included. Clinically appropriate outside laboratory work may also have a separate charge.
When coverage support is part of a program, it means help checking benefits and preparing paperwork requested by a plan. The plan determines approval and payment. Body Good cannot guarantee a coverage result.
This site is an informational and pricing overview only. It takes no payment, collects no protected health information, and operates no intake form. Intake takes place on joinbodygood.com.
Frequently asked questions
What is the starting GLP-1 dose for weight loss?
There is no class-wide starting dose. The answer depends on the exact prescribed product and its current official labeling. Ask the prescriber and follow the pharmacy label.
Can I increase my dose if progress feels slow?
Do not change a dose on your own. The clinician must consider the product label, tolerability, treatment history, and individual risks. Contact the prescribing team for guidance.
Where can I discuss an individual dosing plan?
General information cannot replace a clinical review. Begin Body Good’s secure clinical intake so a licensed clinician can evaluate your situation.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.